Minireview: Computer simulations of blood pressure regulation by the renin-angiotensin system

Endocrinology

Volumn 144, Issue 6, 2003, Pages 2184-2190

  Takahashi, Nobuyuki ^a   Hagaman, John R ^a   Kim, Hyung Suk ^a   Smithies, Oliver ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE REGULATION; COMPUTER SIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEEDBACK SYSTEM; GENE DELETION; GENE INSERTION; GENE TARGETING; GENETIC RISK; HETEROZYGOTE; KALLIKREIN KININ SYSTEM; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; BLOOD PRESSURE; COMPUTER SIMULATION; HUMANS; MODELS, CARDIOVASCULAR; RENIN-ANGIOTENSIN SYSTEM;

EID: 0038577275     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-221045     Document Type: Conference Paper

References (49)

1. Pickering G 1973 Hypertension manual: mechanisms, methods, management. In: Laragh J, ed. Hypertension - definitions, natural histories and consequences. New York: Yorke Medical Books; 3-30
2. Lifton RP 1996 Molecular genetics of human blood pressure variation. Science 272:676-680
3. Lifton RP, Gharavi AG, Geller DS 2001 Molecular mechanisms of human hypertension. Cell 104:545-556
4. Taylor J 1977 The hypertension detection and follow-up program: a progress report. Circ Res 40:I106-I109
5. Ward R 1990 Familial aggregation and genetic epidemiology of blood pressure. In: Laragh J, Brenner B, eds. Hypertension - pathophysiology, diagnosis and management. New York: Raven Press; 81-100
6. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Corvol P 1992 Molecular basis of human hypertension: role of angiotensinogen. Cell 71:169-180
7. Harris H 1970 The principles of human biochemical genetics. New York: American Elsevier Publishing Co. Inc.
8. Epstein CJ 1989 Down syndrome (trisomy 21). In: Scriver CR, ed. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill; 291-326
9. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O 1993 Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 92:2735-2739
10. Krege JH, Kim HS, Moyer JS, Jennette JC, Peng L, Hiller SK, Smithies O 1997 Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 29:150-157
11. Smithies O, Kim HS, Takahashi N, Edgell MH 2000 Importance of quantitative genetic variations in the etiology of hypertension. Kidney Int 58:2265-2280
12. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel JM 1997 A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99:1786-1797
13. Carretero O, Scicli A 1995 The kallikrein-kinin system as a regulator of cardiovascular and renal function. In Laragh J, Brenner B, eds. Hypertension. 2nd ed. New York: Raven Press; 983-999
14. Rose BD, Post TW 2001 Clinical physiology of acid-base and electrolyte disorders. 5th ed. New York: McGraw-Hill
15. Kim HS, Maeda N, Oh GT, Fernandez LG, Gomez RA, Smithies O 1999 Homeostasis in mice with genetically decreased angiotensinogen is primarily by an increased number of renin-producing cells. J Biol Chem 274:14210-14217
16. Gomez RA, Chevalier RL, Everett AD, Elwood JP, Peach MJ, Lynch KR, Carey RM 1990 Recruitment of renin gene-expressing cells in adult rat kidneys. Am J Physiol 259:F660-F665
17. Briggs JB, Schnermann J 1995 Control of renin release and glomerular vascular tone by the juxtaglomerular apparatus. In: Laragh JH, Brenner BM, eds. Hypertension. 2nd ed. New York: Raven Press; 1359-1384
18. Bader M, Ganten D 2000 Regulation of renin: new evidence from cultured cells and genetically modified mice. J Mol Med 78:130-139
19. Kim HS, Lee G, John SW, Maeda N, Smithies O 2002 Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration. Proc Natl Acad Sci USA 99:4602-4607
20. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, Jennette JC, O'Brien DA, Smithies O 1995 Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375:146-148
21. Krege JH, Hodgin JB, Hagaman JR, Smithies O 1995 A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25:1111-1115
22. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, Rockman HA, Maeda N 2001 Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 107:975-984
23. Wong AY, Kulandavelu S, Whiteley KJ, Qu D, Langille BL, Adamson SL 2002 Maternal cardiovascular changes during pregnancy and postpartum in mice. Am J Physiol Heart Circ Physiol 282:H918-H925
24. Esther Jr CR, Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE 1996 Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 74:953-965
25. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ 2000 Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 102:829-832
26. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F 1990 An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346
27. Campbell DJ, Kladis A, Duncan AM 1994 Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23:439-449
28. Davisson RL, Ding Y, Stec DE, Catterall JF, Sigmund CD 1999 Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice. Physiol Genomics 1:3-9
29. Seikaly MG, Arant Jr BS, Seney Jr FD 1990 Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 86:1352-1357
30. Caramori M, Mauer M 2001 Diabetic nephropathy. In: Greenberg A, ed. Primer on kidney diseases. 3rd ed. San Diego: Academic Press; 212-218
31. Borch-Johnsen K, Kreiner S 1987 Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 294:1651-1654
32. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC 1992 Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 41:836-839
33. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860
34. Kvetny J, Gregersen G, Pedersen RS 2001 Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. QJM 94:89-94
35. Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, Urakami T, Uchigata Y, Ohashi Y 2002 Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 55:113-121
36. 2001 Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134:370-379
37. Heart Outcomes Prevention Evaluation Study Investigators. 2000 Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259
38. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parring HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869
39. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P 2001 The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878
40. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F 1994 Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388
41. Doria A, Warram JH, Krolewski AS 1994 Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 43:690-695
42. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F 1996 Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 313:591-594
43. Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M 2001 Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol 12:541-549
44. Jardine AG, Padmanabhan N, Connell JM 1998 Angiotensin converting enzyme gene polymorphisms and renal disease. Curr Opin Nephrol Hypertens 7:259-264
45. Wong TY, Szeto CC, Chow KM, Chan JC, Li PK 2001 Contribution of gene polymorphisms in the renin-angiotensin system to macroangiopathy in patients with diabetic nephropathy. Am J Kidney Dis 38:9-17
46. Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, Krege JH, Meneton P, Marre M, Smithies O, Alhenc-Gelas F 2001 Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 98:13330-13334
47. Brunner-La Rocca HP, Vaddadi G, Esler MD 1999 Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. J Am Coll Cardiol 33:1163-1173
48. Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G 1998 Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 32:1787-1796
49. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA 1997 Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99:1926-1935